Year |
Citation |
Score |
2020 |
Roberts MG, Yu Q, Keunen R, Liu J, Ngae Wong EC, Rastogi CK, Reilly RM, Allen C, Winnik MA. Functionalization of Cellulose Nanocrystals with POEGMA Copolymers via Copper-Catalyzed Azide-Alkyne Cycloaddition for Potential Drug-Delivery Applications. Biomacromolecules. PMID 32364706 DOI: 10.1021/Acs.Biomac.9B01713 |
0.367 |
|
2020 |
Yook S, Cai Z, Jeong JJ, Lu Y, Winnik MA, Pignol JP, Reilly RM. Dual receptor-targeted (DRT) radiation nanomedicine labeled with 177Lu is more potent for killing human breast cancer cells that co-express HER2 and EGFR than single receptor-targeted (SRT) radiation nanomedicines. Molecular Pharmaceutics. PMID 32022567 DOI: 10.1021/Acs.Molpharmaceut.9B01259 |
0.448 |
|
2019 |
Cho H, Al-Saden N, Lam H, Möbus J, Reilly RM, Winnik MA. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing Zr - In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts. Nuclear Medicine and Biology. 84: 11-19. PMID 31931305 DOI: 10.1016/J.Nucmedbio.2019.12.009 |
0.306 |
|
2019 |
Chan C, Fonge H, Lam K, Reilly RM. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. Nuclear Medicine and Biology. PMID 31706737 DOI: 10.1016/J.Nucmedbio.2019.10.001 |
0.384 |
|
2019 |
Ku A, Facca VJ, Cai Z, Reilly RM. Auger electrons for cancer therapy - a review. Ejnmmi Radiopharmacy and Chemistry. 4: 27. PMID 31659527 DOI: 10.1186/S41181-019-0075-2 |
0.318 |
|
2019 |
Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM. MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides to Enable Labeling with 99mTc (I) Tricarbonyl Complex. Molecular Pharmaceutics. PMID 31242384 DOI: 10.1021/Acs.Molpharmaceut.9B00422 |
0.368 |
|
2019 |
Reilly RM. ImmunoPET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy - How Much is Enough? Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 31053683 DOI: 10.2967/Jnumed.119.225854 |
0.301 |
|
2018 |
Aghevlian S, Cai Z, Lu Y, Hedley DW, Winnik MA, Reilly RM. Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 177Lu. Molecular Pharmaceutics. PMID 30589553 DOI: 10.1021/Acs.Molpharmaceut.8B01040 |
0.382 |
|
2018 |
Al-Saden N, Cai Z, Reilly RM. Tumor uptake and tumor/blood ratios for Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1. Nuclear Medicine and Biology. 67: 43-51. PMID 30390575 DOI: 10.1016/J.Nucmedbio.2018.10.002 |
0.349 |
|
2018 |
Al-Saden N, Lam K, Chan C, Reilly RM. Positron-Emission Tomography (PET) of HER2-Positive Breast Cancer Xenografts in Mice with 89Zr-Labeled Trastuzumab-DM1 (T-DM1) - Comparison with 89Zr-Labeled Trastuzumab. Molecular Pharmaceutics. PMID 29957952 DOI: 10.1021/Acs.Molpharmaceut.8B00392 |
0.37 |
|
2018 |
Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu - An EGFR-Targeted Theranostic for Pancreatic Cancer. Molecular Pharmaceutics. PMID 29314858 DOI: 10.1021/Acs.Molpharmaceut.7B01000 |
0.397 |
|
2017 |
Lai P, Cai Z, Pignol JP, Lechtman E, Mashouf S, Lu Y, Winnik MA, Jaffray DA, Reilly RM. Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with (111)In, (177)Lu or (90)Y incorporated into tissue implantable depots. Physics in Medicine and Biology. 62: 8581-8599. PMID 29077574 DOI: 10.1088/1361-6560/Aa9106 |
0.375 |
|
2017 |
Colombo I, Overchuk M, Chen J, Reilly RM, Zheng G, Lheureux S. Molecular imaging in drug development: update and challenges for radiolabeled antibodies and nanotechnology. Methods (San Diego, Calif.). PMID 28743635 DOI: 10.1016/J.Ymeth.2017.07.018 |
0.357 |
|
2017 |
Kwon LY, Scollard DA, Reilly RM. 64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR -Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents. Molecular Pharmaceutics. PMID 28049295 DOI: 10.1021/Acs.Molpharmaceut.6B00963 |
0.343 |
|
2016 |
Cai Z, Yook S, Lu Y, Bergstrom D, Winnik MA, Pignol JP, Reilly RM. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with (177)Lu. Pharmaceutical Research. PMID 27987070 DOI: 10.1007/S11095-016-2082-2 |
0.496 |
|
2016 |
Lai P, Letchman E, Mashouf S, Pignol JP, Reilly RM. Depot system for controlled release of gold nanoparticles with precise intratumoral placement by permanent brachytherapy seed implantation (PSI) techniques. International Journal of Pharmaceutics. PMID 27818245 DOI: 10.1016/J.Ijpharm.2016.11.001 |
0.382 |
|
2016 |
Cai Z, Chattopadhyay N, Yang K, Kwon YL, Yook S, Pignol JP, Reilly RM. (111)In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection. Nuclear Medicine and Biology. 43: 818-826. PMID 27788375 DOI: 10.1016/J.Nucmedbio.2016.08.009 |
0.78 |
|
2016 |
Yook S, Cai Z, Lu Y, Winnik MA, Pignol JP, Reilly RM. Intratumorally Injected 177Lu-Labeled Gold Nanoparticles - Gold Nanoseed Brachytherapy with Application for Neo-Adjuvant Treatment of Locally Advanced Breast Cancer (LABC). Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26848176 DOI: 10.2967/Jnumed.115.168906 |
0.467 |
|
2015 |
Aghevlian S, Boyle AJ, Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons. Advanced Drug Delivery Reviews. PMID 26705852 DOI: 10.1016/J.Addr.2015.12.003 |
0.303 |
|
2015 |
Leyton JV, Gao C, Williams B, Keating A, Minden M, Reilly RM. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Research Reports. 4: 55-9. PMID 26500848 DOI: 10.1016/J.Lrr.2015.07.003 |
0.317 |
|
2015 |
Liu P, Boyle AJ, Lu Y, Adams J, Chi Y, Reilly RM, Winnik MA. Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates. Biomacromolecules. 16: 3613-23. PMID 26469142 DOI: 10.1021/Acs.Biomac.5B01066 |
0.347 |
|
2015 |
Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM. Dual Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Co-Expressing HER2 and EGFR using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 26429962 DOI: 10.2967/Jnumed.115.162339 |
0.369 |
|
2015 |
Spence T, De Souza R, Dou Y, Stapleton S, Reilly RM, Allen C. Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26403800 DOI: 10.1016/J.Jconrel.2015.09.036 |
0.317 |
|
2015 |
Yook S, Cai Z, Lu Y, Winnik MA, Pignol JP, Reilly RM. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu. Molecular Pharmaceutics. 12: 3963-72. PMID 26402157 DOI: 10.1021/Acs.Molpharmaceut.5B00425 |
0.432 |
|
2015 |
Panosa C, Fonge H, Ferrer-Batallé M, Menéndez JA, Massaguer A, De Llorens R, Reilly RM. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting (111)In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Nuclear Medicine and Biology. PMID 26385534 DOI: 10.1016/J.Nucmedbio.2015.08.003 |
0.415 |
|
2015 |
Ngo Ndjock Mbong G, Lu Y, Chan C, Cai Z, Liu P, Boyle AJ, Winnik MA, Reilly RM. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells. Molecular Pharmaceutics. 12: 1951-60. PMID 25919639 DOI: 10.1021/Mp5007618 |
0.366 |
|
2015 |
Reilly RM, Lam K, Chan C, Levine M. Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriers. Bioconjugate Chemistry. 26: 625-32. PMID 25781873 DOI: 10.1021/Acs.Bioconjchem.5B00105 |
0.308 |
|
2015 |
Lam K, Chan C, Done SJ, Levine MN, Reilly RM. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of (111)In-BzDTPA-pertuzumab. Nuclear Medicine and Biology. 42: 78-84. PMID 25459109 DOI: 10.1016/J.Nucmedbio.2014.09.011 |
0.329 |
|
2015 |
Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments. Nuclear Medicine and Biology. 42: 71-7. PMID 25456837 DOI: 10.1016/J.Nucmedbio.2014.10.009 |
0.301 |
|
2014 |
Lam K, Scollard DA, Chan C, Levine MN, Reilly RM. Kit for the preparation of (111)In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Applied Radiation and Isotopes : Including Data, Instrumentation and Methods For Use in Agriculture, Industry and Medicine. 95: 135-142. PMID 25464190 DOI: 10.1016/J.Apradiso.2014.10.011 |
0.397 |
|
2014 |
Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells. Leukemia Research. 38: 1367-73. PMID 25278187 DOI: 10.1016/J.Leukres.2014.09.005 |
0.303 |
|
2014 |
Liu P, Cai Z, Kang JW, Boyle AJ, Adams J, Lu Y, Ngo Ndjock Mbong G, Sidhu S, Reilly RM, Winnik MA. Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers. Biomacromolecules. 15: 715-25. PMID 24506198 DOI: 10.1021/Bm401483A |
0.375 |
|
2014 |
Boyle AJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM. Abstract 103: 64-Cu-NOTA-panitumumab F(ab')2 fragments for PET/CT imaging of pancreatic cancer Cancer Research. 74: 103-103. DOI: 10.1158/1538-7445.Am2014-103 |
0.331 |
|
2013 |
Cai Z, Pignol JP, Chattopadhyay N, Kwon YL, Lechtman E, Reilly RM. Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulation. Medical Physics. 40: 114101. PMID 24320476 DOI: 10.1118/1.4823787 |
0.738 |
|
2013 |
Hoang B, Ekdawi SN, Reilly RM, Allen C. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts. Molecular Pharmaceutics. 10: 4229-41. PMID 24066900 DOI: 10.1021/Mp400315P |
0.42 |
|
2013 |
Panosa C, Tebar F, Ferrer-Batallé M, Fonge H, Seno M, Reilly RM, Massaguer A, De Llorens R. Development of an epidermal growth factor derivative with EGFR blocking activity. Plos One. 8: e69325. PMID 23935985 DOI: 10.1371/Journal.Pone.0069325 |
0.331 |
|
2013 |
Chan C, Cai Z, Reilly RM. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells. Pharmaceutical Research. 30: 1999-2009. PMID 23615858 DOI: 10.1007/S11095-013-1044-1 |
0.378 |
|
2013 |
Lechtman E, Mashouf S, Chattopadhyay N, Keller BM, Lai P, Cai Z, Reilly RM, Pignol JP. A Monte Carlo-based model of gold nanoparticle radiosensitization accounting for increased radiobiological effectiveness. Physics in Medicine and Biology. 58: 3075-87. PMID 23594417 DOI: 10.1088/0031-9155/58/10/3075 |
0.74 |
|
2013 |
Razumienko E, Dryden L, Scollard D, Reilly RM. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates. Breast Cancer Research and Treatment. 138: 709-18. PMID 23525982 DOI: 10.1007/S10549-013-2490-5 |
0.398 |
|
2013 |
Vasdev N, Green DE, Vines DC, McLarty K, McCormick PN, Moran MD, Houle S, Wilson AA, Reilly RM. Positron-emission tomography imaging of the TSPO with [18F]FEPPA in a preclinical breast cancer model Cancer Biotherapy and Radiopharmaceuticals. 28: 254-259. PMID 23350894 DOI: 10.1089/Cbr.2012.1196 |
0.35 |
|
2013 |
Chattopadhyay N, Cai Z, Kwon YL, Lechtman E, Pignol JP, Reilly RM. Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Research and Treatment. 137: 81-91. PMID 23160926 DOI: 10.1007/S10549-012-2338-4 |
0.753 |
|
2013 |
Banerjee N, Fonge H, Mikhail A, Reilly RM, Bendayan R, Allen C. Abstract 3929: Estrone-3-sulphate, a potential novel ligand for targeting breast cancers. Cancer Research. 73: 3929-3929. DOI: 10.1158/1538-7445.Am2013-3929 |
0.37 |
|
2013 |
Yook S, Cai Z, Lu Y, Pignol J, Winnik M, Reilly R. Abstract P4-15-04: Synthesis and characterization of EGFR antibody-mediated tumor targeted “gold nanobombs” for treatment of locally advanced breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-15-04 |
0.432 |
|
2013 |
Mbong GNN, Lu Y, Chan C, Cai Z, Winnik M, Reilly R. Abstract P4-12-14: Metal chelating polymer-conjugated trastuzumab labeled to high specific activity with indium-111 is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of auger electrons Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-12-14 |
0.402 |
|
2013 |
Liu P, Lu Y, Boyle AJ, Jia L, Reilly RM, Winnik MA. Radioimmunoconjugate based on metal-chelating polymers and herceptin fragment for in (111) delivery into breast cancer cells Journal of Controlled Release. 172: e51-e52. DOI: 10.1016/J.Jconrel.2013.08.107 |
0.33 |
|
2012 |
Fasih A, Fonge H, Cai Z, Leyton JV, Tikhomirov I, Done SJ, Reilly RM. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Research and Treatment. 135: 189-200. PMID 22736376 DOI: 10.1007/S10549-012-2137-Y |
0.38 |
|
2012 |
Chattopadhyay N, Fonge H, Cai Z, Scollard D, Lechtman E, Done SJ, Pignol JP, Reilly RM. Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Molecular Pharmaceutics. 9: 2168-79. PMID 22734589 DOI: 10.1021/Mp300016P |
0.759 |
|
2012 |
Ravi A, Reilly RM, Holloway CM, Caldwell CB. Feasibility evaluation of radioimmunoguided surgery of breast cancer. International Journal of Molecular Imaging. 2012: 545034. PMID 22518303 DOI: 10.1155/2012/545034 |
0.318 |
|
2012 |
Hoang B, Reilly RM, Allen C. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells. Biomacromolecules. 13: 455-65. PMID 22191486 DOI: 10.1021/Bm201479T |
0.412 |
|
2012 |
Fonge H, Huang H, Scollard D, Reilly RM, Allen C. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. Journal of Controlled Release : Official Journal of the Controlled Release Society. 157: 366-74. PMID 21982897 DOI: 10.1016/J.Jconrel.2011.09.088 |
0.348 |
|
2011 |
Chan C, Scollard DA, McLarty K, Smith S, Reilly RM. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. Ejnmmi Research. 1: 15. PMID 22214307 DOI: 10.1186/2191-219X-1-15 |
0.303 |
|
2011 |
Cai Z, Chattopadhyay N, Liu WJ, Chan C, Pignol JP, Reilly RM. Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: comparison with manual counting. International Journal of Radiation Biology. 87: 1135-46. PMID 21913819 DOI: 10.3109/09553002.2011.622033 |
0.683 |
|
2011 |
Lechtman E, Chattopadhyay N, Cai Z, Mashouf S, Reilly R, Pignol JP. Implications on clinical scenario of gold nanoparticle radiosensitization in regards to photon energy, nanoparticle size, concentration and location Physics in Medicine and Biology. 56: 4631-4647. PMID 21734337 DOI: 10.1088/0031-9155/56/15/001 |
0.757 |
|
2011 |
Cornelissen B, Darbar S, Hernandez R, Kersemans V, Tullis I, Barber PR, Smart S, Vojnovic B, Reilly R, Vallis KA. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 776-83. PMID 21498540 DOI: 10.2967/Jnumed.110.084392 |
0.385 |
|
2011 |
Scollard DA, Chan C, Holloway CM, Reilly RM. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Nuclear Medicine and Biology. 38: 129-36. PMID 21220136 DOI: 10.1016/J.Nucmedbio.2010.06.010 |
0.391 |
|
2011 |
Lechtman E, Chattopadhyay N, Mashouf S, Cai Z, Reilly R, Pignol J. Gold Nanoparticle Radiosensitization: Optimizing Photon Energy, Nanoparticle Size, and Location for Clinical Translation International Journal of Radiation Oncology*Biology*Physics. 81: S740. DOI: 10.1016/J.Ijrobp.2011.06.1222 |
0.746 |
|
2010 |
Chattopadhyay N, Cai Z, Pignol JP, Keller B, Lechtman E, Bendayan R, Reilly RM. Design and characterization of HER-2-targeted gold nanoparticles for enhanced X-radiation treatment of locally advanced breast cancer. Molecular Pharmaceutics. 7: 2194-206. PMID 20973534 DOI: 10.1021/Mp100207T |
0.771 |
|
2010 |
Akinlolu O, Ottolino-Perry K, McCart JA, Reilly RM. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor. Cancer Biotherapy & Radiopharmaceuticals. 25: 325-33. PMID 20578838 DOI: 10.1089/Cbr.2009.0713 |
0.335 |
|
2010 |
Costantini DL, McLarty K, Lee H, Done SJ, Vallis KA, Reilly RM. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 1084-91. PMID 20554744 DOI: 10.2967/Jnumed.109.072389 |
0.366 |
|
2010 |
Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Molecular Pharmaceutics. 7: 1195-208. PMID 20476759 DOI: 10.1021/Mp100038H |
0.411 |
|
2010 |
Lee H, Hoang B, Fonge H, Reilly RM, Allen C. In vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharmaceutical Research. 27: 2343-55. PMID 20195708 DOI: 10.1007/S11095-010-0068-Z |
0.423 |
|
2010 |
Costantini DL, Villani DF, Vallis KA, Reilly RM. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 477-83. PMID 20150272 DOI: 10.2967/Jnumed.109.069716 |
0.368 |
|
2010 |
Cai Z, Pignol JP, Chan C, Reilly RM. Cellular dosimetry of (111)In using monte carlo N-particle computer code: comparison with analytic methods and correlation with in vitro cytotoxicity. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 51: 462-70. PMID 20150261 DOI: 10.2967/Jnumed.109.063156 |
0.333 |
|
2010 |
Fonge H, Lee H, Reilly RM, Allen C. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy. Molecular Pharmaceutics. 7: 177-86. PMID 19924993 DOI: 10.1021/Mp900201V |
0.414 |
|
2010 |
Eva RJ, Reilly RM. Abstract 4553: Novel bispecific111In-labeled immunoconjugates (bsICs) for imaging HER2/HER3 heterodimerization in breast cancer Cancer Research. 70: 4553-4553. DOI: 10.1158/1538-7445.Am10-4553 |
0.345 |
|
2010 |
Lechtman E, Pignol J, Keller B, Ravi A, Chattopadhyay N, Cai Z, Reilly R. Gold Nanoparticle Radiosensitization is Most Efficient in the Brachytherapy Energy Range Brachytherapy. 9: S46-S47. DOI: 10.1016/J.Brachy.2010.02.061 |
0.746 |
|
2009 |
Cornelissen B, Kersemans V, McLarty K, Tran L, Vallis KA, Reilly RM. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy. Nuclear Medicine and Biology. 36: 811-9. PMID 19720293 DOI: 10.1016/J.Nucmedbio.2009.05.003 |
0.352 |
|
2009 |
Hoang B, Lee H, Reilly RM, Allen C. Noninvasive monitoring of the fate of 111In-labeled block copolymer micelles by high resolution and high sensitivity microSPECT/CT imaging. Molecular Pharmaceutics. 6: 581-92. PMID 19718806 DOI: 10.1021/Mp8002418 |
0.313 |
|
2009 |
McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 1340-8. PMID 19617342 DOI: 10.2967/Jnumed.109.062224 |
0.378 |
|
2009 |
Cornelissen B, Kersemans V, McLarty K, Tran L, Reilly RM. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1. Cancer Biotherapy & Radiopharmaceuticals. 24: 163-73. PMID 19409037 DOI: 10.1089/Cbr.2008.0553 |
0.323 |
|
2009 |
McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 36: 81-93. PMID 18712381 DOI: 10.1007/S00259-008-0923-X |
0.328 |
|
2008 |
Costantini DL, Bateman K, McLarty K, Vallis KA, Reilly RM. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1498-505. PMID 18703606 DOI: 10.2967/Jnumed.108.051771 |
0.348 |
|
2008 |
Cornelissen B, McLarty K, Kersemans V, Reilly RM. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nuclear Medicine and Biology. 35: 645-53. PMID 18678349 DOI: 10.1016/J.Nucmedbio.2008.05.010 |
0.331 |
|
2008 |
Cai Z, Chen Z, Bailey KE, Scollard DA, Reilly RM, Vallis KA. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 49: 1353-61. PMID 18632822 DOI: 10.2967/Jnumed.108.051805 |
0.352 |
|
2008 |
Costantini DL, Hu M, Reilly RM. Peptide motifs for insertion of radiolabeled biomolecules into cells and routing to the nucleus for cancer imaging or radiotherapeutic applications. Cancer Biotherapy & Radiopharmaceuticals. 23: 3-24. PMID 18298325 DOI: 10.1089/Cbr.2007.0430 |
0.345 |
|
2008 |
Cornelissen B, McLarty K, Kersemans V, Scollard DA, Reilly RM. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nuclear Medicine and Biology. 35: 101-10. PMID 18158949 DOI: 10.1016/J.Nucmedbio.2007.09.007 |
0.348 |
|
2008 |
Vallis K, Reilly R, Scollard D, Merante P, Freeman M, Lockwood G, Sabate K, Brade A. A Phase I Trial of 111In-human Epidermal Growth Factor in Patients with Metastatic EGFR-positive Breast Cancer International Journal of Radiation Oncology*Biology*Physics. 72: S178-S179. DOI: 10.1016/J.Ijrobp.2008.06.740 |
0.324 |
|
2007 |
Hu M, Scollard D, Chan C, Chen P, Vallis K, Reilly RM. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nuclear Medicine and Biology. 34: 887-96. PMID 17998090 DOI: 10.1016/J.Nucmedbio.2007.06.010 |
0.406 |
|
2007 |
Lee H, Hu M, Reilly RM, Allen C. Apoptotic epidermal growth factor (EGF)-conjugated block copolymer micelles as a nanotechnology platform for targeted combination therapy. Molecular Pharmaceutics. 4: 769-81. PMID 17867644 DOI: 10.1021/Mp0700559 |
0.388 |
|
2007 |
Bailey KE, Costantini DL, Cai Z, Scollard DA, Chen Z, Reilly RM, Vallis KA. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1562-70. PMID 17704253 DOI: 10.2967/Jnumed.107.044073 |
0.35 |
|
2007 |
Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 48: 1357-68. PMID 17631548 DOI: 10.2967/Jnumed.106.037937 |
0.361 |
|
2007 |
Tang Y, Yang S, Gariépy J, Scollard DA, Reilly RM. Construction and evaluation of the tumor imaging properties of 123I-labeled recombinant and enzymatically generated Fab fragments of the TAG-72 monoclonal antibody CC49 Bioconjugate Chemistry. 18: 677-684. PMID 17361988 DOI: 10.1021/Bc060260R |
0.355 |
|
2007 |
Cornelissen B, Hu M, McLarty K, Costantini D, Reilly RM. Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nuclear Medicine and Biology. 34: 37-46. PMID 17210460 DOI: 10.1016/J.Nucmedbio.2006.10.008 |
0.335 |
|
2007 |
Hu M, Chen P, Wang J, Scollard DA, Vallis KA, Reilly RM. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1). European Journal of Nuclear Medicine and Molecular Imaging. 34: 368-77. PMID 17021818 DOI: 10.1007/S00259-006-0189-0 |
0.331 |
|
2007 |
Jekerle V, Klinkhammer W, Reilly RM, Piquette-Miller M, Wiese M. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemotherapy and Pharmacology. 59: 61-9. PMID 16636798 DOI: 10.1007/S00280-006-0244-3 |
0.307 |
|
2006 |
Hu M, Wang J, Chen P, Reilly RM. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1. Bioconjugate Chemistry. 17: 1280-7. PMID 16984139 DOI: 10.1021/Bc060053R |
0.364 |
|
2006 |
Jekerle V, Klinkhammer W, Scollard DA, Breitbach K, Reilly RM, Piquette-Miller M, Wiese M. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. International Journal of Cancer. Journal International Du Cancer. 119: 414-22. PMID 16646006 DOI: 10.1002/Ijc.21827 |
0.349 |
|
2005 |
Tang Y, Scollard D, Chen P, Wang J, Holloway C, Reilly RM. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine Communications. 26: 427-32. PMID 15838425 DOI: 10.1097/00006231-200505000-00006 |
0.349 |
|
2005 |
Tang Y, Wang J, Scollard DA, Mondal H, Holloway C, Kahn HJ, Reilly RM. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using (111)In-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine and Biology. 32: 51-8. PMID 15691661 DOI: 10.1016/J.Nucmedbio.2004.08.003 |
0.417 |
|
2005 |
Reilly R. The immunoreactivity of radiolabeled antibodies--its impact on tumor targeting and strategies for preservation. Cancer Biotherapy & Radiopharmaceuticals. 19: 669-72. PMID 15665615 DOI: 10.1089/Cbr.2004.19.669 |
0.306 |
|
2005 |
Mehta N, Tang N, Deng H, Scollard D, Jonkman J, Wilson BC, Reilly RM, McCart JA. 75. Molecular Imaging of an EGFP-DRD2-Expressing Vaccinia Virus Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.053 |
0.314 |
|
2004 |
McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, Deng H, Miller M, Xu H, Libutti SK, Alexander HR, Bartlett DL. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 553-61. PMID 15336655 DOI: 10.1016/J.Ymthe.2004.06.158 |
0.343 |
|
2003 |
Wang J, Chen P, Mrkobrada M, Hu M, Vallis KA, Reilly RM. Antisense imaging of epidermal growth factor-induced p21(WAF-1/CIP-1) gene expression in MDA-MB-468 human breast cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging. 30: 1273-80. PMID 12640557 DOI: 10.1007/S00259-003-1134-0 |
0.345 |
|
2002 |
Chen P, Mrkobrada M, Vallis KA, Cameron R, Sandhu J, Hendler A, Reilly RM. Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells. Nuclear Medicine and Biology. 29: 693-9. PMID 12234595 DOI: 10.1016/S0969-8051(02)00325-6 |
0.403 |
|
2002 |
Wang J, Chen P, Su ZF, Vallis K, Sandhu J, Cameron R, Hendler A, Reilly RM. Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nuclear Medicine and Biology. 28: 895-902. PMID 11711308 DOI: 10.1016/S0969-8051(01)00262-1 |
0.413 |
|
Show low-probability matches. |